Statement re Injectables Presentation

RNS Number : 8400I
Hikma Pharmaceuticals Plc
25 November 2008

Hikma Pharmaceuticals PLC - Injectables Presentation

LONDON, 25 November 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) the fast growing multinational pharmaceutical group focused
on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products will today present to investors
and analysts on the company's Global Injectables business. A copy of this presentation and an audio replay will be available on the
company's website at www.hikma.com.

The company will also be attending the HSBC European Healthcare Conference in London on the 26th of November. A copy of this presentation
will also be available on the company's website.
- ENDS -

Enquiries:
Hikma Pharmaceuticals PLC
Susan Ringdal +44 20 7399 2760
Investor Relations Director
Brunswick
Jon Coles/Justine McIlroy +44 20 7404 5959

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both
branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where
it is a market leader and sells across 17 countries, the United States and Europe. In 2007, the Group achieved revenues of $449 million and
profit attributable to shareholders was $63 million. For news and other information, please visit www.hikma.com.

This information is provided by RNS
The company news service from the London Stock Exchange

END

STRMGMZMGDNGRZZ

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024